Although there is no reported evidence of immune responses against mutated IDH1 in AML, therapy targeting IDH1R132H should be equally applicable to IDH1R132H+ AML patients if the neoepitope is processed and presented appropriately, because the codon distribution of IDH1 mutations is not specific to the tissue origin of cancer. Here, IDH1 is linked to cancer.